Pharma Manufacturing Services (CDMOs)
CDMOs support pharma & biotech with process development, scale-up and contract manufacturing.
Evaluating opportunity, differentiation, and long-term growth potential
There has been a secular trend towards greater outsourcing in pharma, and contract development and manufacturing organisations (CDMOs) have benefited.
Rising demand for biologics, complex formulations and advanced therapies is expanding the market, while traditional small-molecule capacity remains under cost and competitive pressure.
We are well known for helping CDMOs model capacity in growing drug classes such as humanised antibody therapeutics and GLP-1s.
We support investors and management teams in assessing opportunities with rigour. Our work includes commercial due diligence, transaction and licensing support, and portfolio strategy. We evaluate market dynamics across modalities and geographies, analyse capacity utilisation, and benchmark contract structures to test whether growth assumptions are realistic.
Our pharma manufacturing services (CDMOs) leads
Our teams combine technical and scientific knowledge with deal execution experience. We assess pipeline demand from pharma and biotech clients, review manufacturing economics and quality track records, and analyse regulatory risk across facilities. This ensures investment theses reflect both client demand trends and the operational realities of delivery.
Beyond transactions, we advise on strategic growth options such as service-line expansion, entry into high-growth modalities, and partnership strategies. By combining deep sector knowledge with practical insight, we help CDMOs and their backers identify sustainable growth opportunities and create long-term value.
News & Insights
